Akèy › Kansè ovè › Arizona › Phoenix
Etid klinik pou Kansè ovè nan Phoenix, AZ
11 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Phoenix (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- Site 0143 - HonorHealth, Phoenix
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Ap rekriteEtid obsèvasyon
- Mayo Clinic, Phoenix
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Mayo Clinic Hospital, Phoenix
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- HonorHealth, Phoenix
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Ap rekriteFaz 3
- Site 0107, Phoenix
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR HonorHealth, Phoenix
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Ap rekriteFaz 3
- Mayo Clinic Arizona, Phoenix
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Mayo Clinic, Phoenix
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- Mayo Clinic Hospital, Phoenix
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Phoenix
- Kansè nan tete25 etid
- Kansè kolorektal25 etid
- Obèsite22 etid
- Kansè Poumon ki pa ti selil20 etid
- Kansè Metastatik20 etid
- Ensifizyans kadyak18 etid
- Kansè pwostat17 etid
- Kansè (tout kalite)17 etid
- Myelom Miltip16 etid
- Kansè pankreyas16 etid
- Maladi kadyovaskilè16 etid
- Maladi Alzheimer15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.